Starten Sie Ihre Suche...


Wir weisen darauf hin, dass wir technisch notwendige Cookies verwenden. Weitere Informationen

I. Medizinische Klinik und Poliklinik

Klinikum / Johannes Gutenberg-Universität Mainz

Forschungsprojekte
Ergebnisse pro Seite:  10

2016 - 2019

A Phase III, open-label, multicenter trial of avelumab (MSB00107118C) as a third-line treatment of unresectable, recurrent, or metastatic gastric or gastroesophageal junction adenocarcinoma
  • Prof. Dr. Markus

2016 - 2020

A Phase III open-label, multicenter trial of maintenance therapy with Avelumab* (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic adenocarcinoma of the stomach or of the gastro-esophageal junction
  • Prof. Dr. Markus

2016 - 2019

Analysis of ACPAs in patients with very early rheumatoid arthritis (VERA) and patients with yet unclassified arthritis (UA) in the Rheumatology network ADAPTHERA
  • Univ.-Prof. Dr. Andreas

2016 - 2020

Regorafenib in Combination with TAS-102 in subjects with metastatic colorectal cancer who have progressed after standard therapy: A multicenter Phase I study.
  • Prof. Dr. Markus

2016 - 2021

Randomized study of the effectiveness of a Cetuximab reexposure in patients with metastatic colorectal carcinoma (RAS The wild type), who responded to a first-line treatment with FOLFIRI Plus Cetuximab
  • Prof. Dr. Markus

2016 - 2018

Guideline Programme-Oncology: Update of the guideline gastric carcinoma (S3)
  • Prof. Dr. Markus

2016 - 2017

Effects of an interferon- and ribavirin- free, direct antiviral therapy on endothelium, metabolism und subclinical inflammation as surrogate markers for hepatitis C associated cardiovascular mortality
  • PD Dr. Tim

2016

1.Follow up of Romanian patients with Gaucher disease type I under ERT with focus on bone metabolism (Überwachung von Patienten mit M. Gaucher Typ 1 unter ERT mit Fokus auf den Knochenstoffwechsel)
  • PD Dr. Anca

2016

Influence of malnutrition on DNA damage and repair in patients with gastrointestinal tumors and their reversibility under nutritional support
  • PD Dr. Anca

2016 - 2018

CFZ 533: An open label study to evaluate the safety and efficacy of 12 week treatment with CFZ533 in patients with Graves' disease
  • Prof. Dr. Georg J.